SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2006. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs.
Management Commentary and Risks
Management commentary is limited to the notification of an increase in the notional allocation of Ordinary Share ADRs for Dr. R Greig on March 24, 2006, at a price of $53.70 per share. No broader outlook, risks, contingencies, or unusual items are discussed in this specific filing.
Key Facts for Investor Verification
- Transaction Date: March 24, 2006.
- Individual Involved: Dr. R Greig.
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Share Price: $53.70 per share.
- Regulatory Basis: Notification in accordance with Disclosure Rule 3.1.4 R (1) (a).